2 girls with Rett dosed in Phase 1/2 trial of NGN-401 gene therapy
Two young girls with Rett syndrome have been dosed with Neurogene‘s gene therapy candidate NGN-401 in a Phase 1/2 clinical trial, with data so far indicating that the treatment has been well tolerated. Another patient is expected to be dosed in the first months of 2024, with interim…